Suppression of cutaneous inflammation by intradermal gene delivery

Rao, K. V. Narasinga; He, Yi-Xun; Kalyanasundaram, Ramaswamy

doi:10.1038/sj.gt.3301622

Cited by 12 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7). In a subsequent study (17), it was reported that intradermal injection of an Sm16-encoding DNA construct into mice resulted in a detectable suppression of LPS-provoked cutaneous inflammation, as well as a general immunosuppressive activity manifested on the level of T-lymphocyte proliferation. While our analysis of the action of a purified Sm16 protein is certainly consistent with inhibition of a cutaneous inflammation, we did not find evidence of a lymphocyte-directed activity of Sm16.…”

Section: Vol 77 2009mentioning

confidence: 98%

The Schistosoma mansoni Protein Sm16/SmSLP/SmSPO-1 Assembles into a Nine-Subunit Oligomer with Potential To Inhibit Toll-Like Receptor Signaling

Brännström¹,

Sellin²,

Holmfeldt³

et al. 2009

Infect Immun

View full text Add to dashboard Cite

The Sm16/SmSLP/SmSPO-1 (Sm16) protein is secreted by the parasite Schistosoma mansoni during skin penetration and has been ascribed immunosuppressive activities. Here we describe the strategy behind the design of a modified Sm16 protein with a decreased aggregation propensity, thus facilitating the expression and purification of an Sm16 protein that is soluble in physiological buffers. The Stokes radii and sedimentation coefficients of recombinant and native proteins indicate that Sm16 is an approximately nine-subunit oligomer. Analysis of truncated Sm16 derivatives showed that both oligomerization and binding to the plasma membrane of human cells depend on multiple C-terminal regions. For analysis of immunomodulatory activities, Sm16 was expressed in Pichia pastoris to facilitate the preparation of a pyrogen/endotoxin-free purified protein. Recombinant Sm16 was found to have no effect on T-lymphocyte activation, cell proliferation, or the basal level of cytokine production by whole human blood or monocytic cells. However, Sm16 exerts potent inhibition of the cytokine response to the Toll-like receptor (TLR) ligands lipopolysaccharide (LPS) and poly(I:C) while being less efficient at inhibiting the response to the TLR ligand peptidoglycan or a synthetic lipopeptide. Since Sm16 specifically inhibits the degradation of the IRAK1 signaling protein in LPS-stimulated monocytes, our findings indicate that inhibition is exerted proximal to the TLR complex.

show abstract

Section: Vol 77 2009mentioning

confidence: 98%

The Schistosoma mansoni Protein Sm16/SmSLP/SmSPO-1 Assembles into a Nine-Subunit Oligomer with Potential To Inhibit Toll-Like Receptor Signaling

Brännström¹,

Sellin²,

Holmfeldt³

et al. 2009

Infect Immun

View full text Add to dashboard Cite

show abstract

“…It was recently demonstrated that a product of filarial nematodes can reduce articular inflammation [11]. Moreover, using a gene delivery strategy, Rao and collaborators [12] showed that the product of an anti-inflammatory cloned gene from Schistosoma mansoni suppresses cutaneous inflammation.…”

Section: Introductionmentioning

confidence: 99%

Anti-inflammatory activity of PAS-1, a protein component of Ascaris suum

2005

View full text Add to dashboard Cite

show abstract

“…Sm16 could also suppress LPS-induced neutrophil infiltration and downregulate production of the proinflammatory cytokines [23]. In addition, a single intradermal injection of a full-length cDNA of Sm16 resulted in a significant suppression of cutaneous inflammation [24]. By using recombinant protein obtained from E. coli , we also demonstrated that rSj16 dramatically suppressed the thioglycollate-mediated recruitment of leukocytes to the peritoneal cavity of BALB/c mice and suppressed thioglycollate-induced peritoneal macrophages maturation, accompanied by marked upregulation of IL-10 and IL-1 receptor antagonist transcripts, and down-regulation of IL-12p35, IL-1 β , and MIP-2 transcripts in peritoneal cells [11].…”

Section: Discussionmentioning

confidence: 99%

Anti-Inflammatory Protein ofSchistosoma japonicumDirects the Differentiation of the WEHI-3B JCS Cells and Mouse Bone Marrow Cells to Macrophages

Mak

et al. 2010

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

Sj16 is an anti-inflammatory protein identified from Schistosoma japonicum. Our previous studies showed that recombinant Sj16 (rSj16) could suppress host's inflammatory responses and inhibit macrophage maturation. In the present study, the effects of rSj16 on the differentiation of the murine myeloid leukemia WEHI-3B JCS cell line and on mouse hematopoiesis were investigated. Our data demonstrated that rSj16 expressed and purified from Escherichia coli could suppress the proliferation of the WEHI-3B JCS cells in a time- and concentration-dependent manner, while not affect the viability of the cells. Further studies indicated that rSj16 induced macrophage differentiation of the WEHI-3B JCS cells, and arrested the cell cycle in the G1/G0 and G2/M phases. The macrophage differentiation of the rSj16-treated WEHI-3B JCS cells was confirmed by their expression of macrophage specific antigen F4/80 and phagocytic activity. Furthermore, our results revealed that rSj16 biased the colony formation of mouse bone marrow cells towards macrophage linage.

show abstract

Suppression of cutaneous inflammation by intradermal gene delivery

Cited by 12 publications

References 27 publications

The Schistosoma mansoni Protein Sm16/SmSLP/SmSPO-1 Assembles into a Nine-Subunit Oligomer with Potential To Inhibit Toll-Like Receptor Signaling

The Schistosoma mansoni Protein Sm16/SmSLP/SmSPO-1 Assembles into a Nine-Subunit Oligomer with Potential To Inhibit Toll-Like Receptor Signaling

Anti-inflammatory activity of PAS-1, a protein component of Ascaris suum

Anti-Inflammatory Protein ofSchistosoma japonicumDirects the Differentiation of the WEHI-3B JCS Cells and Mouse Bone Marrow Cells to Macrophages

Contact Info

Product

Resources

About